Xilia-MP 2 Tablet is a combination oral antidiabetic medication containing Glimepiride 2mg, Metformin 500mg, and Pioglitazone 15mg, indicated for the management of type 2 diabetes mellitus. This formulation leverages the complementary mechanisms of its active ingredients to achieve optimal glycemic control. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake in muscle tissues. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which modulates the transcription of insulin-responsive genes involved in glucose and lipid metabolism. The combined action of these agents addresses multiple pathophysiological defects in type 2 diabetes, including insulin resistance and impaired insulin secretion. Xilia-MP 2 Tablet is typically prescribed as part of a comprehensive diabetes management plan that includes diet, exercise, and regular blood glucose monitoring. Caution is advised in patients with hepatic or renal impairment, heart failure, or a history of lactic acidosis. Adverse effects may include hypoglycemia, gastrointestinal disturbances, weight gain, and edema. Regular follow-up and laboratory evaluations are recommended to ensure safety and efficacy.